The IPO flood keeps ris­ing with 4 more biotechs and a SPAC on their way to Nas­daq

Af­ter a record year for biotech IPOs in 2020, fore­casts were bull­ish on an­oth­er strong year show­ing for pub­lic of­fer­ings — and 2021 hasn’t dis­ap­point­ed so far. Now, a clutch of four biotechs chas­ing rare dis­ease and can­cer and a New York SPAC are ready to join the par­ty.

Three more com­pa­nies filed to head to Nas­daq on Tues­day, as well as a SPAC, with an ad­di­tion­al Dutch biotech fil­ing Fri­day. All in all, ear­ly days in­di­cate an­oth­er big year, at least to start, with 12 com­pa­nies ei­ther pric­ing or fil­ing their IPOs in the first 20 days of Jan­u­ary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.